Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Adenocarcinoma AJCC v7
Prostate Carcinoma Metastatic in the Bone
Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma in the Soft Tissue

Interventions: Drug: Abiraterone Acetate
Drug: Antiandrogen Therapy
Drug: Cabazitaxel
Other: Laboratory Biomarker Analysis
Procedure: Orchiectomy
Other: Pharmacological Study
Drug: Prednisone

First Posted Date: 2018-02-01

Last Posted Date: 2024-11-01

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 223

Registration Number: NCT03419234

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
🇺🇸
Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States

and more 668 locations

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: Onvansertib
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2018-01-29

Last Posted Date: 2024-11-07

Lead Sponsor: Cardiff Oncology

Target Recruit Count: 72

Registration Number: NCT03414034

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Melphalan
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2018-01-26

Last Posted Date: 2024-05-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 265

Registration Number: NCT03412565

Locations: 🇺🇸
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States

and more 60 locations

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

Phase 2

Completed

Conditions: Antibody-mediated Rejection
Lung Transplant Rejection

Interventions: Drug: Tacrolimus
Drug: Belatacept
Drug: ATG
Drug: Mycophenolate Mofetil
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2018-01-02

Last Posted Date: 2022-11-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT03388008

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Daratumumab
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Biological: Peg-asparaginase
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Methotrexate

First Posted Date: 2017-12-27

Last Posted Date: 2023-12-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 47

Registration Number: NCT03384654

Locations: 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

and more 50 locations

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma Without Neuroendocrine Differentiation
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Drug: Prednisone

First Posted Date: 2017-12-04

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT03360721

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Phase 2

Conditions: Castration-resistant Prostate Cancer
Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2017-11-29

Last Posted Date: 2017-12-14

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 220

Registration Number: NCT03356912

Locations: 🇮🇹
University Federico II of Naples, Naples, Italy

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: nivolumab
Drug: rucaparib
Drug: docetaxel
Drug: enzalutamide
Drug: prednisone

First Posted Date: 2017-11-09

Last Posted Date: 2025-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 292

Registration Number: NCT03338790

Locations: 🇺🇸
Local Institution - 0037, Miami, Florida, United States
🇺🇸
Local Institution - 0009, Marietta, Georgia, United States
🇺🇸
Local Institution - 0012, Detroit, Michigan, United States

and more 63 locations